Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

NCT00729183 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: Odanacatib
DRUG: Placebo
DRUG: Vitamin D3
DRUG: Calcium supplement

Sponsor

Merck Sharp & Dohme LLC